Opus Genetics to Participate in Upcoming Investor Conference in April

About this update from Opus Genetics, Inc.

[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/5903b8b33116d080342bdaf2c6a1b0bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xl5Pbyep4pXJ5VZR6DH1.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5903b8b33116d080342bdaf2c6a1b0bd","width":300,"height":129}},"lazy":false},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that George Magrath, M.D., Chief Executive Officer, will participate in the following upcoming investor conference in April.","length":417,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Event:","length":6,"tagName":"p","attribs":{}}]},{"style":"vertical-align:bottom;","val":[{"type":"text","content":"RBC Capital Markets Ophthalmology Conference","length":44,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Location:","length":9,"tagName":"p","attribs":{}}]},{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Virtual","length":7,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Presenter:","length":10,"tagName":"p","attribs":{}}]},{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Dr. George Magrath","length":18,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Date:","length":5,"tagName":"p","attribs":{}}]},{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Thursday, April 3, 2025","length":23,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Time:","length":5,"tagName":"p","attribs":{}}]},{"style":"vertical-align:bottom;","val":[{"type":"text","content":"12:15 p.m. – 12:45 p.m. ET","length":26,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:bottom;","...

More updates from Opus Genetics, Inc.